Myasthenia gravis after botulinum toxin A for meige syndrome

Movement Disorders

Volumn 15, Issue 4, 2000, Pages 736-738

  Tarsy, Daniel ^a   Bhattacharyya, Neil ^a   Borodic, Gary ^b  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BACLOFEN; BENZATROPINE; BOTULINUM TOXIN A; CHOLINERGIC RECEPTOR ANTIBODY; DIPHENHYDRAMINE; EDROPHONIUM; NEOSTIGMINE; PREDNISONE;

AGED; BARIUM MEAL; BLEPHAROSPASM; CASE REPORT; CLINICAL FEATURE; DOSE RESPONSE; ELECTROMYOGRAPHY; EXTRAOCULAR MUSCLE; FACE MUSCLE; FEMALE; HUMAN; MEIGE DISEASE; MUSCLE BIOPSY; MYASTHENIA GRAVIS; NOTE; OROFACIAL DYSKINESIA; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; BOTULINUM TOXIN TYPE A; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; LONG-TERM CARE; MEIGE SYNDROME; MYASTHENIA GRAVIS;

EID: 0033910543     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/1531-8257(200007)15:4<736::AID-MDS1023>3.0.CO;2-9     Document Type: Note

References (15)

1. Sanders DB, Massey EW, Buckley EG. Botulinum toxin for blepharospasm: single-fiber EMG studies. Neurology 1986;36:545-547.
2. Lange DJ, Brin MF, Warner CL, et al. Distant effects of local injection of botulinum toxin. Muscle Nerve 1987;10:552-555.
3. Olney RK, Aminoff MJ, Gelb DJ, et al. Neuromuscular effects distant from the site of botulinum neurotoxin injection. Neurology 1988;38:1780-1783.
4. Garner CG, Straube A, Witt TN, et al. Time course of distant effects of local injections of botulinum toxin. Mov Disord 1993; 8:33-37.
5. Girlanda P, Vita G, Nicolosi C, et al. Botulinum toxin therapy: distant effects on neuromuscular transmission and autonomic nervous system. J Neurol Neurosurg Psychiatry 1992;55:844-845.
6. Ansved T, Odergren T, Borg K. Muscle fiber atrophy in leg muscles after botulinum toxin type A for treatment of cervical dystonia. Neurology 1997;48:1440-1442.
7. Emmerson J. Botulinum toxin for spasmodic torticollis in a patient with myasthenia gravis. Mov Disord 1994;9:367-379.
8. Erbguth F, Claus D, Engelhardt A, et al. Systemic effect of local botulinum toxin injections unmasks subclinical Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 1993;56: 1235-1236.
9. Bakheit AMO, Ward CD, McLellan DL. Generalized botulism-like syndrome after intramuscular injections of botulinum toxin type A: a report of two cases. J Neurol Neurosurg Psychiatry 1997;62:198.
10. Mezaki T, Kaji R, Kohara N, et al. Development of general weakness in a patient with amyotrophic lateral sclerosis after focal botulinum toxin injection. Neurology 1996;46:845-846.
11. Tuite PJ, Lang AE. Severe and prolonged dysphagia complicating botulinum toxin A injections for dystonia in Machado-Joseph disease. Neurology 1996;46:846.
12. Borodic G. Myasthenic crisis after botulinum toxin. Lancet 1998; 352:1832.
13. Seybold ME. Myasthenia gravis. JAMA 1983;250:2516-2521.
14. Fonseca V, Harvard CWH. The natural course of myasthenia gravis. BMJ 1990;300:1409-1410.
15. Sanders DB, Howard JF Jr. Disorders of neuromuscular transmission. In: Bradley WG, Daroff RB, Fenichel GM, Marsden CD, eds. Neurology in Clinical Practice, 2nd ed. Boston, MA: Butterworth-Heinemann, 1996.